HRMY 25.95 ▼ -2.55% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Harmony Biosciences Inc.

    NASDAQ: HRMY · Real-Time Price · USD
    25.95
    -0.68 (-2.55%)
    At close: Oct 16, 2025, 3:59 PM
    25.95
    0.00%
    After-hours: Oct 16, 2025, 07:41 PM EDT
    -2.55%
    Bid 25.81
    Market Cap 1.49B
    Revenue (ttm) 772.53M
    Net Income (ttm) 180.9M
    EPS (ttm) 3.1
    PE Ratio (ttm) 8.37
    Forward PE 6.73
    Analyst Buy
    Dividends n/a
    Ask 26.44
    Volume 907,492
    Avg. Volume (20D) 816,475.2
    Open 26.59
    Previous Close 26.63
    Day's Range 25.91 - 26.97
    52-Week Range 25.91 - 41.61
    Beta 0.79
    Ex-Dividend Date n/a

    About HRMY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol HRMY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for HRMY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Harmony Biosciences Inc. is scheduled to release its earnings on Oct 28, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 weeks ago
    -16.56%
    Harmony Biosciences Holdings shares are trading lo... Unlock content with Pro Subscription
    1 month ago
    -5.11%
    Harmony Biosciences shares are trading lower. Needham lowered its price target on the stock from $49 to $48.
    news image

    1 day ago · seekingalpha.com

    3 Biotech Stocks I Am Accumulating

    The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call tra...

    news image

    3 weeks ago · zacks.com

    HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal

    Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.

    news image

    3 weeks ago · benzinga.com

    Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday

    U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Wednesday.

    news image

    3 weeks ago · reuters.com

    Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial

    Harmony Biosciences said on Wednesday its experimental drug for a type of rare genetic disorder failed to meet the main goal in a late-stage trial, sending its shares down 8% before the bell.

    news image

    3 weeks ago · businesswire.com

    Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

    PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN00...

    news image

    1 month ago · seekingalpha.com

    Harmony Biosciences Holdings, Inc. (HRMY) Presents at Cantor Global Healthcare Conference 2025 Transcript

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Cantor Global Healthcare Conference 2025 September 4, 2025 2:10 PM EDT Company Participants Jeffrey Dayno - President, CEO & Director Sandip Kapadia -...

    news image

    1 month ago · businesswire.com

    Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

    PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy ...

    news image

    1 month ago · businesswire.com

    Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

    PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global ...

    news image

    1 month ago · seekingalpha.com

    Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug

    Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could drive...

    news image

    2 months ago · seekingalpha.com

    Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Adam Zaeske - Executive VP & Chief Commercial Officer Brennan Doyle - ...

    Add to Watchlist